Ask AI
ProCE Banner Activity

Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM

Podcast

Bispecific antibody therapy continues to rapidly change the care of patients with relapsed/refractory multiple myeloma (RRMM). In this podcast, learners will hear 2 oncology specialty pharmacists discuss recent evidence-based information and updated safe-use guidelines and implementation of bispecific antibodies incorporated into RRMM management. They will describe the major toxicities associated with bispecific antibodies targeting BCMA and GPRC5, including CRS, ICANS, and infection; how they work within their institutions to reduce the risk of these adverse events from occurring; and their experience with monitoring for and treating these adverse events when they arise.

Released: July 23, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize key toxicities such as cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, cytopenias, infections, and agent-specific effects, using current guideline-based tools and protocols

  • Interpret clinical trial data and real-world evidence to differentiate bispecific antibodies by targets, dosing strategies, safety profiles, and administration nuances, facilitating optimal agent selection and sequencing in relapsed/refractory multiple myeloma

  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements

  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations

Financial Disclosures

Primary Author

Syeda Saba Kareem, PharmD, BCOP: consultant/advisor/speaker: Janssen, Pfizer, Regeneron, Sanofi.

Sara A. Scott, PharmD, BCOP: consultant/advisor/speaker: GlaxoSmithKline, Pfizer, Sanofi.